Topic: nonalcoholic steatohepatitis (NASH)
Glympse Bio, a startup that builds bioengineered in vivo sensors for disease, has emerged from stealth with a $22 million series A round.
Corbus bought over 600 compounds from Jenrin Discovery to fuel 1 to 2 new clinical programs in inflammatory and fibrotic diseases annually from 2020.
Viking Therapeutics’ lead lipid disorder asset met its endpoints in a midstage trial, dropping cholesterol and liver fat levels in patients with NAFLD.
Andrew Cheng took the top spot at Akero Therapeutics, not long after it raised $65 million to push its NASH candidate into phase 2 trials.
Diagnostic maker Echosens is teaming up with a consortium of health systems to develop a real-world evidence model to help standardize care for NASH.
Shire has quietly cut the trial of an FDA fast-tracked fatty liver disease drug, although it’s not giving much away about what happened.
HotSpot Therapeutics, a new drug discovery venture exploring protein regulation, has kicked off with $45 million in series A financing.
Gilead’s senior director of clinical research, Adrian Ray, has moved to Nimbus Therapeutics to become its senior vice president of discovery biology.
Gilead is eagerly awaiting phase 3 data for its rheumatoid arthritis drug filgotinib that could be an antidote for the biotech’s hepatitis C hangover.
Shares in Gemphire more than doubled after its lead drug gemcabene aced a trial in patients with high triglycerides, setting up a phase 3 test.